Highlights from the XXV International Congress of the World Federation of Hemophilia. May 19-24, 2002, Seville, Spain.
Lusher
Jeanne M
JM
D000818:Animals; D030801:Animals, Genetically Modified; D001323:Autoantibodies / Q000009:adverse effects / Q000096:biosynthesis; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D005164:Factor IX / Q000096:biosynthesis / Q000276:immunology; D005169:Factor VIII / Q000096:biosynthesis / Q000276:immunology; D005260:Female; D015316:Genetic Therapy; D006467:Hemophilia A / Q000209:etiology / Q000235:genetics / Q000628:therapy; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008595:Menorrhagia / Q000188:drug therapy; D009154:Mutation / Q000235:genetics; D011994:Recombinant Proteins / Q000096:biosynthesis; D012737:Sex Factors; D013552:Swine / Q000235:genetics / Q000378:metabolism; D013585:Synovitis / Q000473:pathology / Q000532:radiotherapy; D014842:von Willebrand Diseases / Q000188:drug therapy
D001323:Autoantibodies; D006490:Hemostatics; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX; D003894:Deamino Arginine Vasopressin